Personal information

Keywords

CLL, Myeloma, Flow Cytometry

Countries

United Kingdom

Activities

Collapse all

Works (50 of 137)

Items per page:
Page 1 of 3

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.

2016 | Journal article
DOI: 10.1186/s13063-016-1581-0
PMID: 27645620
Contributors: Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Minimal residual disease is an independent predictor for 10-year progression-free and overall survival in CLL.

2016-10 | Journal article
PMID: 27697770
Contributors: Kwok M; Rawstron AC; Varghese A; Evans PA; O'Connor SJ; Doughty C; Newton DJ; Moreton P; Hillmen P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

2016-09 | Journal article
DOI: 10.1001/jamaoncol.2016.3160
PMID: 27632282
Contributors: Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

2016-04 | Journal article
DOI: 10.1038/leu.2015.313
PMID: 26639181
PMC: PMC4832072
Contributors: Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

2016-02 | Journal article
DOI: 10.3324/haematol.2015.128215
PMID: 26471484
PMC: PMC4938335
Contributors: de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Assessment of minimal residual disease in myeloma and the need for a consensus approach.

2016-01 | Journal article
DOI: 10.1002/cyto.b.21272
PMID: 26202864
Contributors: Rawstron AC; Paiva B; Stetler-Stevenson M
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

2016-01 | Journal article
DOI: 10.1002/cyto.b.21271
PMID: 26147493
Contributors: Rawstron AC; de Tute RM; Haughton J; Owen RG
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

2015-04 | Journal article
DOI:

10.1002/cyto.b.21249

PMID:

25907102
Contributors: Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

2015-04 | Journal article
DOI:

10.1136/annrheumdis-2014-206496

PMID:

25854586
Contributors: Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

2015-03 | Journal article
DOI:

10.1182/blood-2014-07-590166

PMID:

25645353

PMC:

PMC4375716
Contributors: Rawstron AC; Gregory WM; de Tute RM; Davies FE; Bell SE; Drayson MT; Cook G; Jackson GH; Morgan GJ; Child JA et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.

2015-03 | Journal article
DOI:

10.3324/haematol.2014.118786

PMID:

25480495

PMC:

PMC4349291
Contributors: Weinhold N; Meissner T; Johnson DC; Seckinger A; Moreaux J; Försti A; Chen B; Nickel J; Chubb D; Rawstron AC et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

2015-01 | Journal article
DOI:

10.1002/cyto.b.21228

PMID:

25619868
Contributors: Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

2014-12 | Journal article
DOI:

10.1002/ajh.23831

PMID:

25132630
Contributors: Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

2014-08 | Journal article
DOI:

10.1182/blood-2014-04-566521

PMID:

24939658
Contributors: Hill QA; Rawstron AC; de Tute RM; Owen RG
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Response to Dr Bredemeier's letter.

2014-06 | Journal article
DOI:

10.1136/annrheumdis-2014-205405

PMID:

24632007
Contributors: Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

2014-05 | Journal article
DOI:

10.1136/annrheumdis-2013-204417

PMID:

24385201
Contributors: Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.

2014-04 | Journal article
DOI:

10.1182/blood-2013-10-532283

PMID:

24449210
Contributors: Weinhold N; Johnson DC; Rawstron AC; Försti A; Doughty C; Vijayakrishnan J; Broderick P; Dahir NB; Begum DB; Hosking FJ et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

2014-04 | Journal article
DOI:

10.1200/JCO.2013.49.6547

PMID:

24638012
Contributors: Hillmen P; Gribben JG; Follows GA; Milligan D; Sayala HA; Moreton P; Oscier DG; Dearden CE; Kennedy DB; Pettitt AR et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Reply to M. Roschewski et al.

2014-02 | Journal article
DOI:

10.1200/JCO.2013.53.0980

PMID:

24419132
Contributors: Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Feyler S et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.

2014-01 | Journal article
PMID:

24443001
Contributors: Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

2013-07 | Journal article
DOI:

10.1158/1535-7163.MCT-12-1173

PMID:

23598530
Contributors: Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

2013-07 | Journal article
DOI:

10.1200/JCO.2012.46.2119

PMID:

23733781
Contributors: Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.

2013-05 | Journal article
DOI:

10.1182/blood-2012-12-471698

PMID:

23596047
Contributors: Vardi A; Dagklis A; Scarfò L; Jelinek D; Newton D; Bennett F; Almeida J; Rodriguez-Caballero A; Allgood S; Lanasa M et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Immunoglobulin M concentration in Waldenstrom macroglobulinemia: correlation with bone marrow B cells and plasma cells.

2013-04 | Journal article
DOI:

10.1016/j.clml.2013.02.018

PMID:

23523273
Contributors: de Tute RM; Rawstron AC; Owen RG
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Monoclonal B cell lymphocytosis--what does it really mean?

2013-03 | Journal article
DOI:

10.1007/s11899-012-0144-z

PMID:

23307471
Contributors: Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.

2013-03 | Journal article
DOI:

10.1111/bjh.12197

PMID:

23293871
Contributors: Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis.

2013-03 | Journal article
DOI:

10.1136/annrheumdis-2012-202454

PMID:

23144447
Contributors: Das S; Fernandez Matilla M; Dass S; Buch MH; Rawstron AC; Vital EM; Emery P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

2013-01 | Journal article
DOI:

10.1038/leu.2012.216

PMID:

23041722
Contributors: Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop.

2013-01 | Journal article
DOI:

10.1111/bjh.12102

PMID:

23150997
Contributors: Owen RG; Kyle RA; Stone MJ; Rawstron AC; Leblond V; Merlini G; Garcia-Sanz R; Ocio EM; Morra E; Morel P et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

In vitro generation of long-lived human plasma cells.

2012-12 | Journal article
DOI:

10.4049/jimmunol.1103720

PMID:

23162129
Contributors: Cocco M; Stephenson S; Care MA; Newton D; Barnes NA; Davison A; Rawstron A; Westhead DR; Doody GM; Tooze RM
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Clinical cytometry in Europe, 2012.

2012-11 | Journal article
DOI:

10.1002/cyto.b.21049

PMID:

23090912
Contributors: Kappelmayer J; Rawstron A; Szöllosi J; Gratama JW
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

2012-10 | Journal article
DOI:

10.1158/1535-7163.MCT-12-0087

PMID:

22807577
Contributors: Elkins K; Zheng B; Go M; Slaga D; Du C; Scales SJ; Yu SF; McBride J; de Tute R; Rawstron A et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

2012-09 | Journal article
DOI:

10.1038/leu.2012.120

PMID:

22552007

PMC:

PMC3437410
Contributors: van Dongen JJ; Lhermitte L; Böttcher S; Almeida J; van der Velden VH; Flores-Montero J; Rawstron A; Asnafi V; Lécrevisse Q; Lucio P et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

2012-05 | Journal article
DOI:

10.1200/JCO.2011.35.9695

PMID:

22493413
Contributors: Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Translocation t(14;16) in IgM multiple myeloma.

2011-11 | Journal article
DOI:

10.1111/j.1365-2141.2011.08687.x

PMID:

21501138
Contributors: Owen RG; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

2011-10 | Journal article
DOI:

10.1002/art.30466

PMID:

21618204
Contributors: Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Defining IgM multiple myeloma.

2011-08 | Journal article
DOI:

10.1002/ajh.22061

PMID:

21761439
Contributors: Owen RG; Feyler S; O'Connor SJ; Bond LR; de Tute RM; Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

2011-03 | Journal article
DOI:

10.1111/j.1365-2141.2010.08317.x

PMID:

21231927
Contributors: Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Heterogeneity of histological transformation events in Waldenstrom's macroglobulinemia (WM) and related disorders.

2011-02 | Journal article
DOI:

10.3816/CLML.2011.n.042

PMID:

21856554
Contributors: Owen RG; Bynoe AG; Varghese A; de Tute RM; Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

Arthritis & Rheumatism
2011-02 | Journal article
DOI:

10.1002/art.30152

Part of ISSN:

0004-3591
Contributors: Edward M. Vital; Andrew C. Rawstron; Shouvik Dass; Karen Henshaw; Julie Madden; Paul Emery; Dennis McGonagle
Source: Self-asserted source
Andy Rawstron via Crossref Metadata Search

Occult B-cell lymphoproliferative disorders.

2011-01 | Journal article
DOI:

10.1111/j.1365-2559.2010.03702.x

PMID:

21261685
Contributors: Rawstron AC
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing.

2010 | Journal article
DOI:

10.1002/cyto.b.20534

PMID:

20839337
Contributors: Rawstron AC; Shingles J; de Tute R; Bennett F; Jack AS; Hillmen P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection.

2010 | Journal article
DOI:

10.1002/cyto.b.20556

PMID:

20839336
Contributors: Nieto WG; Almeida J; Teodosio C; Abbasi F; Allgood SD; Connors F; Rachel JM; Ghia P; Lanasa MC; Rawstron AC et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).

2010 | Journal article
DOI:

10.1002/cyto.b.20533

PMID:

20839333
Contributors: Rawstron AC; Shanafelt T; Lanasa MC; Landgren O; Hanson C; Orfao A; Hillmen P; Ghia P
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Human peripheral blood B-cell compartments: a crossroad in B-cell traffic.

2010 | Journal article
DOI:

10.1002/cyto.b.20547

PMID:

20839338
Contributors: Perez-Andres M; Paiva B; Nieto WG; Caraux A; Schmitz A; Almeida J; Vogt RF Jr; Marti GE; Rawstron AC; Van Zelm MC et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Prevalence of monoclonal B-cell lymphocytosis: a systematic review.

2010 | Journal article
DOI:

10.1002/cyto.b.20538

PMID:

20839330

PMC:

PMC2963430
Contributors: Shim YK; Middleton DC; Caporaso NE; Rachel JM; Landgren O; Abbasi F; Raveche ES; Rawstron AC; Orfao A; Marti GE et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvement.

2010-12 | Journal article
DOI:

10.1111/j.1365-2141.2010.08386.x

PMID:

20880115
Contributors: Boll M; Parkins E; O'Connor SJ; Rawstron AC; Owen RG
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis.

2010-12 | Journal article
DOI:

10.1182/blood-2010-07-294975

PMID:

20855867
Contributors: Crowther-Swanepoel D; Corre T; Lloyd A; Gaidano G; Olver B; Bennett FL; Doughty C; Toniolo D; Caligaris-Cappio F; Calligaris-Cappio F et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

2010-09 | Journal article
DOI:

10.1038/leu.2010.141

PMID:

20596033
Contributors: Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J et al.
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central

Extramedullary plasmacytoma with a t(11;14)(q13;q32) and aggressive clinical course.

2010-07 | Journal article
DOI:

10.3109/10428194.2010.486454

PMID:

20496997
Contributors: Parkins E; Boll M; O'Connor SJ; Rawstron AC; Owen RG
Source: Self-asserted source
Andy Rawstron via Europe PubMed Central
Items per page:
Page 1 of 3
How many people are using ORCID?